Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)

被引：0
|
作者：
Herzberg, B. [1 ]
Johnson, M. [2 ]
Kim, C. G. [3 ]
Tolcher, A. [4 ]
Rodon, J. [5 ]
Mantia, C. [6 ]
Liu, J. [7 ]
Tripathi, A. [8 ]
Rodriguez, L. Paz-Ares [9 ]
Rouge, T. De la Motte [10 ]
Choi, C. M. [11 ]
Han, J. Y. [12 ]
Kwei, L. [13 ]
Liu, E. [14 ]
Sachdev, J. [14 ]
O'Quigley, M. [14 ]
White, M. [15 ]
Beaupre, D. [16 ]
Kim, H. R. [17 ]
机构：
[1] Columbia Univ, Dept Hematol & Oncol, Herbert Irving Comprehens Canc Ctr, New York, NY USA
[2] Sarah Cannon Res Inst, SCRI Dev Innovat Div, Nashville, TN USA
[3] Yonsei Canc Ctr, Dept Internal Med, Div Med Oncol, Seoul, South Korea
[4] NEXT Oncol, Clin Res, San Antonio, TX USA
[5] MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Div Canc Med, Houston, TX USA
[6] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Ctr Canc Therapeut Innovat, Dept Med Oncol, Boston, MA USA
[7] St Vincents Hosp Sydney, Med Oncol, Kinghorn Canc Ctr, Darlinghurst, NSW, Australia
[8] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[9] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[10] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France
[11] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[12] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[13] IDEAYA Biosci, Biometr, San Francisco, CA USA
[14] IDEAYA Biosci, Clin Dev, San Francisco, CA USA
[15] IDEAYA Biosci, Res, San Francisco, CA USA
[16] IDEAYA Biosci, Clin Dev, San Diego, CA USA
[17] Yonsei Univ, Yonsei Canc Ctr, Div Med Oncol, Dept Internal Med,Coll Med, Seoul, South Korea
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114979
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
501LBA
引用
收藏
页码：S176 / S177
页数：2
相关论文
共 50 条
  • [31] Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
    Moreno, V.
    Gil-Martin, M.
    Johnson, M.
    Aljumaily, R.
    Lopez Criado, P.
    Northfelt, D. W.
    Crittenden, M.
    Jabbour, S.
    Rosen, L.
    Garrido Lopez, P.
    Hervas Moron, A.
    Rietschel, P.
    Mohan, K. K.
    Li, J.
    Stankevich, E.
    Rowlands, T.
    Feng, M.
    Lowy, I.
    Fury, M. G.
    ANNALS OF ONCOLOGY, 2018, 29 : 414 - 414
  • [32] Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC)
    Shaw, Alice T.
    Ghizdavescu, Doru
    Jain, Minish
    Volovat, Constantin
    Subramaniam, Deepa
    Shuster, Dale
    Jin, Xiaoping
    Dutta, Dipen
    Pai, Seema
    von Roemeling, Reinhard
    CANCER RESEARCH, 2012, 72
  • [33] Soluble BTN2A1 as a potential predictive biomarker of immune checkpoint inhibitor efficacy in advanced non-small cell lung cancer (NSCLC).
    Rochigneux, Philippe
    Chretien, Anne Sophie
    Rossille, Delphine
    Chanez, Brice
    Billon, Emilien
    Fattori, Stephane
    Corre, Romain
    Pakradouni, Jihane
    Goncalves, Anthony
    Fest, Thierry
    Madroszyk, Anne
    Olive, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Biomarker based phase I study of Apricoxib, a potent COX-2 inhibitor in combination with erlotinib in non-small cell lung cancer (NSCLC) patients
    Reckamp, Karen
    Patel, Ravi
    Gitlitz, Barbara
    Chen, Lin
    Jezior, Deborah
    Zaknoen, Sara
    CANCER RESEARCH, 2009, 69
  • [35] A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor Dinaciclib (SCH 727965) in patients with non-small cell lung cancer (NSCLC)
    Warren, Stephen L.
    Nemunaitis, John
    Stephenson, Joe
    Samson, Benoit
    Joy, Anil A.
    Zhang, Da
    Statkevich, Paul
    Jou, Ying-Ming
    Yao, Siu-Long
    Navarro, Mark
    Bannerji, Rajat
    Edelman, Martin J.
    CANCER RESEARCH, 2011, 71
  • [36] Paclitaxel versus oral vinorelbine in patients with advanced non-small cell lung cancer (NSCLC) with performance status (PS) 2: A randomized phase II study
    Syrigos, K. N.
    Bacoyiannis, C.
    Makatsoris, T.
    Bamias, A.
    Klouvas, G.
    Nicolaides, C.
    Boukovinas, I.
    Linardou, E.
    Fountzilas, G.
    Kosmidis, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Anamorelin in patients with advanced non-small cell lung cancer and cachexia: Results from the phase III studies ROMANA 1 and 2
    Temel, Jennifer S.
    Currow, David Christopher
    Fearon, Kenneth
    Yan, Ying
    Friend, John
    Abernethy, Amy Pickar
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29)
  • [38] FIRST PHASE 2 RESULTS OF AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTE (TIL; LN-145) MONOTHERAPY IN PATIENTS WITH ADVANCED, IMMUNE CHECKPOINT INHIBITOR-TREATED, NON-SMALL CELL LUNG CANCER (NSCLC)
    Schoenfeld, Adam
    Lee, Sylvia
    Paz-Ares, Luis
    Doger, Bernard
    Gettinger, Scott
    Haefliger, Simon
    Orcurto, Angela
    Sukari, Ammar
    Papa, Sophie
    Rodriguez Moreno, Juan Francisco
    Finckenstein, Friedrich Graf
    Jagasia, Madan
    Fiaz, Rana
    Sulur, Giri
    Chen, Guang
    Gontcharova, Viktoria
    He, Kai
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A486 - A487
  • [39] A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC)
    Johnson, M.
    Wacheck, V.
    Hussein, M.
    McCleod, M.
    Daniel, D.
    Waterhouse, D.
    Gil, M.
    Strickland, D.
    Bendell, J. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] A RANDOMIZED, PHASE 2 STUDY OF PACLITAXEL (P) AND CARBOPLATIN (C) ± CONATUMUMAB (CON) FOR FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)
    Paz-Ares, L.
    Balint, B.
    de Boer, R.
    van Meerbeeck, J. P.
    Wierzbicki, R.
    Desouza, P. L.
    Galimi, F.
    Haddad, V.
    Hei, Y.
    Ramlau, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 137 - 137
12345